Rabbit Polyclonal TOP2A Antibody

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P04223(TOP2A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P04223(TOP2A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

TOP2A (DNA topoisomerase II alpha) is a nuclear enzyme critical for DNA replication, transcription, and chromosome segregation by regulating DNA topology during cell division. The TOP2A gene encodes this enzyme, which is highly expressed in proliferating cells, particularly during the G2/M phase of the cell cycle. Dysregulation of TOP2A is implicated in cancer development, as its overexpression or genetic alterations (e.g., amplifications, deletions) are linked to tumor aggressiveness, genomic instability, and therapeutic resistance.

Antibodies targeting TOP2A are widely used in research and diagnostics to assess protein expression levels in tissues, often via immunohistochemistry (IHC). In clinical settings, TOP2A status is evaluated alongside HER2 in breast cancer to guide treatment decisions, as TOP2A co-amplification with HER2 may predict sensitivity to anthracycline-based chemotherapy. Additionally, TOP2A antibodies help study drug mechanisms, such as the action of topoisomerase inhibitors (e.g., etoposide, doxorubicin), which trap TOP2A-DNA complexes to induce lethal DNA breaks. However, TOP2A testing remains controversial due to variability in antibody performance, assay standardization challenges, and conflicting evidence regarding its standalone prognostic value. Despite this, it remains a biomarker of interest in oncology for understanding cell proliferation dynamics and optimizing targeted therapies.